This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
LAZCLUZE® (lazertinib)
Medical Information
RYBREVANT® (amivantamab-vmjw)
Last Updated: 04/20/2026
SUMMARY
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), RYBREVANT®
(amivantamab-vmjw), LAZCLUZE® (lazertinib) - PALOMA-2 Study - Minimum requirement to access interactive content: Adobe Acrobat Reader.
- The executive summary infographic of the iPDF content is provided below.
PRODUCT LABELING
- RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT+Faspro-pi.pdf.
- RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.
- LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf.